Compare Moderna, Inc. (MRNA) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs DENTSPLY SIRONA Inc — how do they compare? Moderna, Inc. trades at $220.99 (market cap $78.65B), while DENTSPLY SIRONA Inc trades at $8.77 (market cap $1.73B). The key difference: Moderna, Inc. is far larger — about 45.5× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and DENTSPLY SIRONA Inc for 72 Days on average.
| MRNA | XRAY | |
|---|---|---|
Market Cap | $78.65B | $1.73B |
Volume | 37,373,437 | 6,198,582 |
Sector | Health | Health |
52-Week High | $203.46 | $14.68 |
52-Week Low | $22.36 | $8.52 |
Typical Hold Time | 59 Days | 72 Days |
Enterprise Value | $74.80B | $3.80B |
Dividend Yield | — | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $214.50, up 9.17% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics, with revenue declining from $18.9B in 2022 to $1.92B in 2025. Recent Nasdaq-100 inclusion creates institutional demand, though Citigroup downgraded to Sell citing valuation concerns after a 500% 2026 rally. The company continues beating EPS expectations despite net losses.
Outlook remains bifurcated between technical strength and fundamental challenges. The cancer vaccine pipeline offers growth potential, but persistent losses and high valuations create headwinds. Near-term momentum may continue from index fund inflows, though profitability concerns warrant caution for long-term investors.
Dentsply Sirona (XRAY) trades at $8.73, near its 52-week low, with a bearish technical signal and negative profitability metrics. The company reported a Q2 2026 earnings beat but faces declining revenue and negative net income margins. Recent news highlights institutional stake increases and ongoing restructuring efforts amid a challenging dental market environment.
The outlook remains cautious due to persistent margin pressure and sales declines, though the consensus price target of $13.40 suggests potential upside. Key risks include competitive pressures and execution of the turnaround plan, while institutional buying indicates some long-term confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
